NEW YORK (GenomeWeb) – Quidel reported after the close of the market on Monday that its first quarter revenues rose 46 percent year over year, thanks largely to higher sales of immunoassay, molecular, and specialty products.

For the three months ended March 31, revenues rose to $73.7 million from $50.3 million in Q1 2016, and beat the average analysts' estimate of $62.0 million.

The firm said that influenza revenues rose 112 percent to $40.8 million year over year, thanks to a severe and longer-than-usual respiratory disease season.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.